CEP68

Across TCGA pan-cancer cohorts, CEP68 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CEP68’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CEP68 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CEP68 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

HNSC, PDAC, and COAD are the cancer types where CEP68 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEP68 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−0.458	<.001	11	view →
PDAC	Female	II,III,IV	−0.912	<.001	9	view →
COAD	All	III,IV	−0.664	<.001	9	view →
LUAD	Male	III,IV	−0.528	<.001	8	view →
LSCC	Male	III,IV	−0.389	<.001	8	view →
CCRCC	Male	III,IV	−0.264	<.001	8	view →
OV	All	All	−0.807	.039	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

CEP68–HNSC

Open the HNSC breakdown →